Delonix is a leading biotech leveraging cutting-edge synthetic biology to engineer the next generation bacterial vaccines. The company possesses a versatile genetic engineering suite validated across more than 15 pathogens. Leveraging these capabilities, Delonix has built several proprietary platforms, including OMV Plus™ (next-gen engineered OMV vaccines), BioDVax and ProBVax. Delonix’s lead asset, an OMV Plus™-derived Meningococcal B (MenB) vaccine, has completed its IND filing, with global clinical trials set to initiate in Australia and China (www.delonixbio.com).